Zoryve 0.3 %

Roflumilast, the active ingredient in ZORYVE 0.3% Foam, is a phosphodiesterase-4 (PDE4) inhibitor presented as a 0.3% foam for topical use. It is used to treat seborrheic dermatitis and plaque psoriasis in adults and children aged 9 years and older. GNH USA supplies ZORYVE 0.3% Foam as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

ZORYVE 0.3% Foam is a prescription medication designed to address specific skin conditions. It is applied once daily to the affected areas and is known for its steroid-free formulation, making it a suitable option for long-term use.

ZORYVE 0.3% Foam is a topical medication used to manage skin conditions by reducing inflammation and other symptoms.

- Seborrheic Dermatitis: Reduces flaking, redness, and itching associated with this condition. - Plaque Psoriasis: Helps manage symptoms such as scaling and inflammation on the scalp and body. - Atopic Dermatitis: Used to treat mild to moderate eczema, reducing inflammation and discomfort.

ZORYVE 0.3% Foam may cause various side effects, ranging from common to serious.

Common Side Effects: - Headache: A frequent side effect that may occur during treatment. - Diarrhea: Some users may experience gastrointestinal discomfort. - Nausea: Mild to moderate nausea can occur. - Upper respiratory tract infections: Symptoms such as a runny nose or sore throat may be observed. - Application site pain: Discomfort or pain at the site where the foam is applied. - Insomnia: Difficulty sleeping may be experienced by some users. - Urinary tract infections: Some users may develop UTIs.

Serious or Rare Side Effects: - Severe allergic reactions: Rare but possible, requiring immediate medical attention. - Liver function abnormalities: Monitoring liver function is advised, especially in patients with pre-existing liver conditions.

ZORYVE 0.3% Foam should be used with caution and under medical supervision.

- Allergies: Do not use if allergic to roflumilast or any of the ingredients. - Liver problems: Use with caution in patients with liver impairment. - Pregnancy: Consult a healthcare provider before use during pregnancy. - Breastfeeding: Avoid applying to the nipple or areola to prevent contact with the baby. - Children: Not recommended for children under 9 years of age for seborrheic dermatitis. - Flammability: Avoid fire, flame, and smoking during and after application. - Store at room temperature: Protect from light and moisture, and keep out of reach of children.

ZORYVE 0.3% Foam may interact with other medications, potentially affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: Can increase the risk of side effects. - Strong CYP3A4 inducers: May reduce the effectiveness of roflumilast.

Moderate Interactions (Monitor Closely): - Other PDE4 inhibitors: May enhance the risk of side effects. - Medications affecting liver function: Requires monitoring of liver function tests. - Immunosuppressants: May increase the risk of infections.